Myocardial high-energy phosphate metabolism is altered after treatment with anthracycline in childhood

Cardiology in the Young

Volumn 10, Issue 6, 2000, Pages 610-617

  Eidenschink, Andrea B ^a   Schröter, Gerrit ^a   Müller Weihrich, Stefan ^a   Stern, Heiko ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Anthracyclines; Cardiotoxicity; High energy phosphates; Magnetic resonance spectroscopy; Metabolism

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTHRACYCLINE; CREATINE PHOSPHATE; PHOSPHATE;

ADOLESCENT; ADULT; ARTICLE; CHILD; DRUG EFFECT; ENERGY METABOLISM; FEMALE; HEART MUSCLE; HUMAN; MALE; METABOLISM; NEOPLASM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRESCHOOL CHILD;

ADENOSINE TRIPHOSPHATE; ADOLESCENT; ADULT; ANTHRACYCLINES; CHILD; CHILD, PRESCHOOL; ENERGY METABOLISM; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MYOCARDIUM; NEOPLASMS; PHOSPHATES; PHOSPHOCREATINE;

EID: 0034320533     PISSN: 10479511     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1047951100008891     Document Type: Article

References (37)

1. Boring CC, Squires TS, Tong T, Mongomery S. Cancer statistics, 1994. CA Cancer J Clin 1994; 44: 7-26
2. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SE Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324: 808-815
3. Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Med Ped Oncol 1995; 24: 352-361
4. Von Hoff DD, Rozencweig M, Piccart M. The cardiotoxicity of anticancer agents. Semin Oncol, 1982; 9: 23-33
5. Olson RD, Mushlin PS. Doxorubicin cardioroxicity: analysis of prevailing hypotheses. FASEB J 1990; 4: 3076-3086
6. Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmac Ther 1990; 47: 219-231
7. Fu LX, Waagstein F, Hjaimarson A. A new insight into adriamyin-induced cardiotoxicity. Intern J Cardiol 1990; 29: 15-20
8. Goormaghtigh E, Huart P, Praet M, Brasseur R, Ruysschaert JM. Structure of the adriamycin-cardiolipin complex- role in mitochondrial toxicity. Biophys Chem 1990; 35: 247-257
9. Papadopoulou LC, Tsitsoglou AS. Mitochondrial cytochrome c oxidase as a target site for daunomycin in k-562 cells and heart tissue. Cancer Res 1993; 53: 1972-1978
10. 31P NMR spectroscopy in chronic adriamycin cardiotoxicity. Magn Res Med 1991; 17: 69-81
11. 31P NMR of perfused rat hearts. Biochem Biophys Res Comm 1983; 110: 339-347
12. Nicolay K, Aue WP, Seelig J, van Echteld CJA, Ruigrok TJC, de Kruijff B. Effects of the anti-cancer drug adriamycin on the energy metabolism of rat heart as measured by in vivo 31P-NMR and implications for adriamycin-induced cardiotoxicity. Biochim Biophys Acta 1987; 929: 5-13
13. Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the cardiology committee of the childrens cancer study group. Pediatrics 1992; 89: 942-949
14. Colan SD, Parness I, Spevac PJ, Sanders SP. Developmental modulation of myocardial mechanics: age- and growth-related alterations in afterload and contractility. J Am Coll Cardiol 1992; 19: 619-629
15. Ordidge RJ, Connely A, Lohman JAB. Image-selected in vivo spectroscopy (ISIS): a new technique for spatially selective NMR spectroscopy. J Magn Reson 1985; 66: 283-294
16. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Circulation 1992; 86: 1810-1818
17. Auffermann W, Chew WM, Wolfe CL, et al. Normal and diffusely abnormal myocardium in humans: functional and metabolic characterization with p-31 MR spectroscopy and cine MR imaging. Radiology 1991; 179: 253-259
18. 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 1998; 97: 2536-2542
19. 31P magnetic resonance spectroscopy. Circulation 1995; 92: 15-23
20. 31P rotating frame NMR. Proc Natl Acad Sci USA 1987; 84: 4283-4287
21. 31P MR spectroscopy in hypertrophic cardiomyopathy: comparison with TI-201 myocardial perfusion imaging. Am Heart J 1993; 125: 1323-1328
22. 31P magnetic resonance spectroscopy. Lancet 1991; 338: 973-976
23. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac cardiotoxicity 4 to 20 years after completing anthracycline therapy. YAMA 1991; 266: 1672-1677
24. Bu'Lock FA, Mott MG, Oakhill A, Martin RP. Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms and pathophysiology. Br Heart J 1995; 73: 340-350
25. Lipshultz SE, Sanders SP, Goorin AM, Krischer JP, Sallan SE, Colan SD. Monitoring for anthracycline cardiotoxicity. Pediatrics 1994; 93: 433-437
26. Nysom K, Holm K, Lipsitz SR, et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol 1998; 16: 545-550
27. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The pediatric ancology group experience. J Clin Oncol 1997; 15: 1544-1552
28. Sorensen K, Levitt G, Bull C, Chessells J, Sullivan I. Anthracycline dose in childhood acute lymphoblastic leukemia: issue of early survival versus late cardiotoxicity. J Clin Oncol 1997; 15: 61-68
29. Lang D, Hilger F, Binswanger J, Andelfmger G, Hartmann E. Late effects of anthracycline therapy in childhood in relation to the function of the heart at rest and under physical stress. Eur J Pediatr 1995; 154: 340-345
30. Sung RYT, Huang GY, Sing MK, et al. Echocardiographic evaluation of cardiac function in paediatric oncology patients treated with or without anthracyclines. Int J Cardiol 1997; 60: 239-248
31. Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphological changes. Cancer Treat Rep 1978; 62: 865-872
32. Pihkala J, Sariola H, Saarinen UM. Myocardial function and postmortem myocardial histology in children given anthracycline therapy for cancer. Ped Hematol Oncol 1994; 11: 259-269
33. AH MK, Ewer MS, Gibbs HR, Swafford J, Graff KL. Late doxorubicin-associated cardiotoxicity in children. Cancer 1994; 74: 182-188
34. Bu'Lock FA, Mott MG, Oakhill A, Martin RP. Left ventricular diastolic filling patterns associated with progressive anthracycline-induced myocardial damage: a prospective study. Pediatr Cardiol 1999; 252-263
35. Goens MB, Karr SS, Seibel N, Martin GR. Ultrasound myocardial tissue caracterisation by integrated backscatter in children treated with anthracyclines. Pediatr Cardiol 1999; 20: 264-270
36. Hashimoto I, Fukiko I, Miura M, et al. Automatic border detection identifies subclinical cardiotoxicity in children with malignancy. Circulation 1999; 99: 2367-2370
37. Carrio I, Estorch M, Lopez-Pousa A. Assessing anthracycline cardiotoxicity in the 1990s. Eur J Nucl Med 1996; 23: 359-364